Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

274 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Evaluation of an infectivity standard for real-time quality control of human immunodeficiency virus type 1 quantitative micrococulture assays. Participating Laboratories of The AIDS Clinical Trials Group.
Scott WA, Brambilla D, Siwak E, Beatty C, Bremer J, Coombs RW, Farzadegan H, Fiscus SA, Hammer SM, Hollinger FB, Khan N, Rasheed S, Reichelderfer PS. Scott WA, et al. Among authors: hammer sm. J Clin Microbiol. 1996 Sep;34(9):2312-5. doi: 10.1128/jcm.34.9.2312-2315.1996. J Clin Microbiol. 1996. PMID: 8862609 Free PMC article.
Detection of replication-competent human immunodeficiency virus type 1 (HIV-1) in cultures from patients with levels of HIV-1 RNA in plasma suppressed to less than 500 or 50 copies per milliliter.
Demeter LM, Bosch RJ, Coombs RW, Fiscus S, Bremer J, Johnson VA, Erice A, Jackson JB, Spector SA, Squires KM, Fischl MA, Hughes MD, Hammer SM. Demeter LM, et al. Among authors: hammer sm. J Clin Microbiol. 2002 Jun;40(6):2089-94. doi: 10.1128/JCM.40.6.2089-2094.2002. J Clin Microbiol. 2002. PMID: 12037070 Free PMC article. Clinical Trial.
Variability and prognostic values of virologic and CD4 cell measures in human immunodeficiency virus type 1-infected patients with 200-500 CD4 cells/mm(3) (ACTG 175). AIDS Clinical Trials Group Protocol 175 Team.
Lathey JL, Hughes MD, Fiscus SA, Pi T, Jackson JB, Rasheed S, Elbeik T, Reichman R, Japour A, D'Aquila RT, Scott W, Griffith BP, Hammer SM, Katzenstein DA. Lathey JL, et al. Among authors: hammer sm. J Infect Dis. 1998 Mar;177(3):617-24. doi: 10.1086/514250. J Infect Dis. 1998. PMID: 9498440 Clinical Trial.
Changes in virologic markers as predictors of CD4 cell decline and progression of disease in human immunodeficiency virus type 1-infected adults treated with nucleosides. AIDS Clinical Trials Group Protocol 175 Team.
Fiscus SA, Hughes MD, Lathey JL, Pi T, Jackson B, Rasheed S, Elbeik T, Reichman R, Japour A, Byington R, Scott W, Griffith BP, Katzenstein DA, Hammer SM. Fiscus SA, et al. Among authors: hammer sm. J Infect Dis. 1998 Mar;177(3):625-33. doi: 10.1086/514248. J Infect Dis. 1998. PMID: 9498441 Clinical Trial.
The contribution of assay variation and biological variation to the total variability of plasma HIV-1 RNA measurements. The Women Infant Transmission Study Clinics. Virology Quality Assurance Program.
Brambilla D, Reichelderfer PS, Bremer JW, Shapiro DE, Hershow RC, Katzenstein DA, Hammer SM, Jackson B, Collier AC, Sperling RS, Fowler MG, Coombs RW. Brambilla D, et al. Among authors: hammer sm. AIDS. 1999 Nov 12;13(16):2269-79. doi: 10.1097/00002030-199911120-00009. AIDS. 1999. PMID: 10563712
The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team.
Katzenstein DA, Hammer SM, Hughes MD, Gundacker H, Jackson JB, Fiscus S, Rasheed S, Elbeik T, Reichman R, Japour A, Merigan TC, Hirsch MS. Katzenstein DA, et al. Among authors: hammer sm. N Engl J Med. 1996 Oct 10;335(15):1091-8. doi: 10.1056/NEJM199610103351502. N Engl J Med. 1996. PMID: 8813039 Free article. Clinical Trial.
Predictors of virologic and clinical outcomes in HIV-1-infected patients receiving concurrent treatment with indinavir, zidovudine, and lamivudine. AIDS Clinical Trials Group Protocol 320.
Demeter LM, Hughes MD, Coombs RW, Jackson JB, Grimes JM, Bosch RJ, Fiscus SA, Spector SA, Squires KE, Fischl MA, Hammer SM. Demeter LM, et al. Among authors: hammer sm. Ann Intern Med. 2001 Dec 4;135(11):954-64. doi: 10.7326/0003-4819-135-11-200112040-00007. Ann Intern Med. 2001. PMID: 11730396 Clinical Trial.
Changes in HIV-1 subtypes B and C genital tract RNA in women and men after initiation of antiretroviral therapy.
Fiscus SA, Cu-Uvin S, Eshete AT, Hughes MD, Bao Y, Hosseinipour M, Grinsztejn B, Badal-Faesen S, Dragavon J, Coombs RW, Braun K, Moran L, Hakim J, Flanigan T, Kumarasamy N, Campbell TB; A5185s Team. Fiscus SA, et al. Clin Infect Dis. 2013 Jul;57(2):290-7. doi: 10.1093/cid/cit195. Epub 2013 Mar 26. Clin Infect Dis. 2013. PMID: 23532477 Free PMC article. Clinical Trial.
274 results